Market closed · Next open: Monday 9:30 AM ET
Last update: Nov 20, 2026, 6:14 PM ET
Merck & Co., Inc.
$133.72▲ 0.69% today
Market Closed

Why Merck & Co., Inc. (MRK) stock moved

No significant move on Nov 20, 2026 (+0.7%, close-to-close). Latest notable session: Nov 19, 2026.

Latest session▼ 3.6% · Nov 19, 2026 close

Why Merck & Co., Inc. (MRK) fell 3.6% on November 19, 2026

Merck & Co., Inc. (MRK) fell 3.6% on November 19, 2026, closing at $132.81 versus $137.78 the prior session (close-to-close, from daily closes). As the market digested a strategic research collaboration with Isomorphic Labs announced via Business Wire, alongside updates on vaccine research expansion into kidney cancer presented at the Jefferies London Healthcare Conference. Volume reached 3.3M shares (1.50x normal pace at this stage of session), suggesting moderate institutional attention to the news flow. Source: Business Wire.

Updated
Prior close
$137.78
Nov 19, 2026 close
$132.81
Change (close-to-close)
−$4.97
−3.61%
As first detected · Nov 19, 2026, 11:02 AM ET

Merck fell 2.74% to $134.00 as the market digested a strategic research collaboration with Isomorphic Labs announced via Business Wire, alongside updates on vaccine research expansion into kidney cancer presented at the Jefferies London Healthcare Conference. Volume reached 3.3M shares (1.50x normal pace at this stage of session), suggesting moderate institutional attention to the news flow.

What to watch next: Merck earnings release scheduled for February 2, 2027 (consensus EPS $1.78); watch for guidance updates on Isomorphic collaboration timeline and kidney cancer vaccine data readiness.

Source: Business Wire · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved MRK

  1. −3.9%Merck disclosed discontinuation of nemtabrutinib (MK-1026), an oral BTK inhibitor and centerpiece of its $2.7 billion ArQule acquisition, after an independent Data Monitoring Committee determined risks outweighed benefits in the Phase 3 BELLWAVE-011 trial for blood cancers.
  2. +3.9%Following its October 29 Q3 beat (revenue $18.09B, up 5% YoY) and raised full-year 2026 guidance, compounded by a $50 million equity investment in Personalis and an expanded Moderna collaboration on individualized neoantigen therapy (V940/mRNA-4157), per web sources.
  3. +3.8%Merck reported third-quarter earnings that topped analyst estimates and raised full-year adjusted profit guidance, driven by stronger-than-expected sales from Keytruda—including its newer injectable form Qlex—and growth from Winrevair (per CNBC, WSJ).
  4. −3.2%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  5. +3.8%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  6. −3.3%As profit-taking pressures persist following a multi-month rally that had lifted the stock near $150 in late September.

Merck & Co., Inc. (MRK) shares rose 0.7% to $133.72 as of November 21, 2026, a slight gain from the prior close of $132.81. BestStocks flagged the session as a major change for MRK. Below, we break down what changed for MRK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

MRK climbed 0.7% to $133.72

MRK rose 0.7% in its latest session, moving from $132.81 to $133.72.

RiskSector-Wide MoveLow confidence
Rel. volume
1.6×
Above Avg
Vs peers
Top 4 of 7 peers
In Line With Peers
Market cap
$329.7B
New York Stock Exchange
Analyst target
$159
+19.2% vs price
Price chart
Oct 21 – Nov 20
VVNNNNFVNNVVEN$133$142$151Oct 21Oct 29Nov 5Nov 13Nov 20
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Merck & Co., Inc. investors

For Merck & Co., Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.7% session move; Positive price momentum. Weighing against that: Merck fell 2.74% to $134.00 as the market digested a strategic research collaboration with Isomorphic Labs announced via Business Wire, alongside updates on vaccine research expansion into kidney cancer presented at the Jefferies London Healthcare Conference; Merck shares fell 2.16% to $141.19 as profit-taking pressures persist following a multi-month rally that had lifted the stock near $150 in late September. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in MRK's fundamentals. Wall Street's consensus price target sits at $159.45, implying +19.2% upside from $133.72. BestStocks rates the overall signal quality low (47/100). With earnings roughly 73 days out, the next report is the most likely near-term test of the move.

MRK price reaction

MRK last traded at $133.72, up $0.91 (+0.69%) from the previous close of $132.81. The session traded on 1.6× average volume (above avg), so the move carried above-average conviction. Its healthcare peer group moved a median +0.9% over the same stretch, leaving MRK essentially in line with peers. Over the past month the stock has ranged between $132.81 and $150.36, and it currently sits about 5% of the way up that band.

Bullish and bearish analyst opinions on Merck & Co., Inc. (MRK)

The consensus analyst price target on Merck & Co., Inc. (MRK) is $159.45, 19.2% above the recent $133.72. Over the past 90 days analysts logged 0 upgrades, 18 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MRK line up.

The bullish case

  • Wall Street's consensus price target of $159.45 implies +19.2% upside from $133.72.
  • The Street's most bullish target is $180.00 (+34.6%).
  • Positive 0.7% session move.
  • Positive price momentum.
  • Merck reported third-quarter earnings that topped analyst estimates and raised full-year adjusted profit guidance, driven by stronger-than-expected sales from Keytruda—including its newer injectable form Qlex—and growth from Winrevair (per CNBC, WSJ).

The bearish case

  • The most bearish analyst target is $105.00 (-21.5%).
  • Merck fell 2.74% to $134.00 as the market digested a strategic research collaboration with Isomorphic Labs announced via Business Wire, alongside updates on vaccine research expansion into kidney cancer presented at the Jefferies London Healthcare Conference.
  • Merck shares fell 2.16% to $141.19 as profit-taking pressures persist following a multi-month rally that had lifted the stock near $150 in late September.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $159+19.2%
= 18 maintains
Freedom Broker maintained Hold · 2026-11-02
SEC filings watch
8-K2026-11-18
Material event — review for impact
high
10-Q2026-11-04
Quarterly financial results
medium
8-K2026-10-29
Material event — review for impact
high
8-K2026-10-13
Material event — review for impact
high
Peer context
MRK+0.7%
LLY-0.3%
UNH+2.8%
JNJ+1.2%
PFE-0.5%
ABBV+0.9%

Previous notable changes for MRK

Valuation2026-11-18-3.9%via Business Wire ↗
Merck disclosed discontinuation of nemtabrutinib (MK-1026), an oral BTK inhibitor and centerpiece of its $2.7 billion ArQule acquisition, after an independent Data Monitoring Committee determined risks outweighed benefits in the Phase 3 BELLWAVE-011 trial for blood cancers. The decision to shut down the entire BELLWAVE program, combined with significant insider selling by EVP Richard Deluca (58,185 shares, ~34% stake reduction), drove the stock down 2.33% to $140.03. The decline also coincided with the stock falling below its 50-day moving average.
News2026-11-18-3.9%
Merck board member Thomas Glocer retiring May 2027; Douglas Baker appointed independent lead director.
News2026-11-17-0.8%
Merck announced its first-quarter 2027 dividend payment to shareholders.
News2026-11-13+0.6%
Merck receives EU CHMP positive opinion to expand ENFLONSIA clesrovimab approval to children up to 24 months with severe RSV vulnerability.
Upcoming catalysts & outlook
Next earnings
2027-02-02 (est.)
in 73 days
10-Q Filing (est.)
2027-02-03
Medium impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
High
from change events

Frequently asked questions about MRK

Why did Merck & Co., Inc. (MRK) stock move?

Merck & Co., Inc. (MRK) fell 3.6% on November 19, 2026, closing at $132.81 versus $137.78 the prior session (close-to-close, from daily closes). As the market digested a strategic research collaboration with Isomorphic Labs announced via Business Wire, alongside updates on vaccine research expansion into kidney cancer presented at the Jefferies London Healthcare Conference. Volume reached 3.3M shares (1.50x normal pace at this stage of session), suggesting moderate institutional attention to the news flow. Source: Business Wire.

How much did MRK stock rise?

MRK gained 0.69% ($0.91) versus the prior close of $132.81, last trading at $133.72 on 1.6× average volume.

When is Merck & Co., Inc.'s next earnings date?

MRK's next earnings report is estimated for 2027-02-02 — about 73 days away.

What is the analyst price target for MRK?

The consensus analyst price target for MRK is $159.45, about 19.2% above the current $133.72. Over the past 90 days, analysts recorded 0 upgrades, 18 maintains, and 0 downgrades.

Is the MRK move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median +0.9% against MRK's +0.7%. MRK ranks top 4 of 7 peers.

How BestStocks tracks MRK

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRK-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.